| SLB |
Report |
Total Revenue (Q2 2026) |
IN-LINE |
pred ~$8.75B vs. cons $8.681B |
MEDIUM |
| SLB |
Report |
Adj. Operating EPS (Q2 2026) |
BEAT |
pred ~$0.52 vs. cons $0.506 |
MEDIUM |
| SLB |
Report |
Adj. EBITDA (Q2 2026) |
BEAT |
pred ~$1.82B vs. cons $1.774B |
MEDIUM |
| SLB |
Guide |
Q3 2026 Revenue (direction) |
UNCHANGED |
guide ~$8.9-9.1B sequential growth vs. cons $8.88B |
MEDIUM |
| SLB |
Guide |
FY 2026 Revenue (if reinstated) |
UNKNOWN |
likely still suspended; if given ~$36.5-37.0B vs. cons $36.46B |
LOW |
| SLB |
Guide |
Middle East recovery tone |
UNCHANGED |
gradual/cautious; no pre-war level recovery in Q3 |
HIGH |
| SLB |
Guide |
Digital ARR (Q2 2026) |
BETTER |
~$1.05-1.08B vs. $1.02B at Q1 end |
MEDIUM |
| SLB |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.1% |
— |
MEDIUM |
| SLB |
Return |
5-day cumulative residual |
+1.5% (STABILIZE) |
STABILIZE — beat absorbed quickly; no FY guide reinstatement limits follow-through; sell-side won't aggressively revise H2 until conflict resolves |
MEDIUM |